drugset / Trial / NCT01298128

NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment

NCT01298128

Terminated 70 enrolled University of Toronto
RandomizedParallel-groupOpen-labelTreatment

Summary

The newly designed contraceptive ring, Nuvaring has a lower total steroid dose, and medications are delivered locally. It has been proven to be as safe and effective as the combined OCP in ovarian suppression and preventing ovulation with fewer side effects due to minimal systemic absorption. Following a single vaginal insertion, steroid concentrations remain stable for up to 4 weeks. It is hypothesized that Nuvaring may, therefore lead to better compliance, tolerability and acceptance by patients requiring ovarian suppression prior to COH for IVF.

Timeline

Start
2006-02
Primary completion
2010-03
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Marvelon Small molecule 30 ug Oral
Subject NuvaRing Other / unclassified Other

Indications